Navigation Links
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Date:11/18/2008

Randomized study will enroll newly diagnosed, elderly AML patients

PRINCETON, N.J., Nov. 18 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

The first patient was enrolled by Eric Feldman, MD at the Weill Medical College of Cornell University and New York Presbyterian Hospital. Dr. Feldman was an investigator involved in the Phase 1 study with CPX-351 in patients with advanced leukemias. "We are pleased to be involved in this Phase 2 study based on the encouraging results seen in the Phase 1 study," said Dr. Feldman. "It's important to develop new treatment options for patients and CPX-351 incorporates two of the most active agents used in the treatment of AML."

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ratio for use in combination chemotherapy. CPX-351 represents a new approach to developing drug combinations in which drug ratios are pre-selected based on synergistic anti-tumor activity observed preclinically and where the ratios are maintained in patients through Celator's proprietary CombiPlex(R) technology platform.

The Phase 2 study will be conducted in patients with newly diagnosed AML, greater than or equal to 60 but <76 years of age, who are able to tolerate intensive chemotherapy. This randomized (2:1) study is designed to compare CPX-351 to the conventional method of administering cytarabine and daunorubicin, commonly referred to as "7+3." The reference "7+3" refers to the administration days of the drugs (cytarabine is administered as a 7 day continuous infusion and daunorubicin is administered on days 1, 2 and 3). CPX-351 is administer
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Raptor Pharmaceuticals Provides Update on Targeting Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... "Scintillator Market by Composition of Material, Application (Healthcare, ... others), End Product (Personal Instrument, Hand-Held Instruments, Fixed, ... and Analysis to 2013 - 2020", published by MarketsandMarkets, the ... CAGR of 5.62% from 2014 to 2020, and ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... for individuals living with West Nile Virus and ... or immune compromised, PURCHASE, N.Y., Sept. 9 ... State University supported by the Division of,Vector-Borne Infectious ... (CDC) has demonstrated that AHCC(R) (Active Hexose Correlated,Compound) ...
... SAN DIEGO, Sept. 9 Ardea Biosciences, Inc.,(Nasdaq: ... presented on,the Company,s lead mitogen-activated ERK kinase (MEK) inhibitor, ... at,the Gaylord Palms Resort & Convention Center in Orlando., ... follows:, Date/Time: Tuesday, October 7, 2008 from 10:30 ...
Cached Medicine Technology:Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus 2Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus 3Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous dress ... of brown evening dresses for worldwide clients. ... discounted prices, up to 50% off. , All ... are carefully made according to most fashionable styles. In ... offers pretty accessories: wedding shoes, dancing shoes, sandals, boots ...
(Date:7/13/2014)... a professional supplier of funeral products. According to the company’s ... the global market. Recently, the company has announced its latest ... offer for all the newly released items. , Despite ... made with superb materials. As is commonly noted, a nice ... the departed saint. MillionaireCasket.com is always here to help. , ...
(Date:7/13/2014)... the best treatment and variations in the quality of ... blood cancer patients still varies widely between regions within ... in European adults to date, published in The ... 5-year survival for most cancers of the blood has ... the approval of new targeted drugs in the early ...
(Date:7/13/2014)... County, NC (PRWEB) July 13, 2014 ... of its newest location, the Carolinas HealthCare System - ... facility replaces the aged Anson Community Hospital in Wadesboro. ... is approximately three miles from the previous facility. Situated ... single-story floorplan that includes an emergency room drop-off, helipad, ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3
... since 1959 , , TUESDAY, Nov. 25 (HealthDay News) ... the risk of chronic obstructive pulmonary disease (COPD), which ... U.S. researchers studied the job and health records of ... who worked on diesel trains (engineers, brakemen, conductors) were ...
... Good(TM) Campaign Reaches $1 Million Dollar Donation Goal and Collects ... , , NEW YORK, Nov. ... pleased to announce the donation of one million dollars to ... Against Hunger. The donation was made possible by the ...
... officials,convened today at a briefing hosted by the Pittsburgh ... recommendations of the Southwestern,PA Regional HIV/AIDS Needs Assessment study. ... insight and perspective on the impact of,the assessment,s findings ... Kathi Boyle, Executive Director of Pittsburgh AIDS Task Force, ...
... Of all the threats facing U.S. soldiers in combat, ... improvised explosive devices (IED,s). At the 61st Meeting of ... week in San Antonio, Naval Research Laboratory (NRL) scientist ... risk of traumatic brain injury for U.S. soldiers and ...
... FRANCISCO, Nov. 25 ECO2 Plastics, Inc.,(OTC Bulletin Board: ... plastics are recycled, today announced that it has received ... Administration (FDA), which,affirms the effectiveness of its proprietary waterless ... recycled plastic flake,to be used in food packaging applications. ...
... Margins Shrunk; Nearly Half Lost Money , , ... - 47 percent - posted overall losses at the end of 2007, ... the New Jersey Hospital Association,s Financial Status of New Jersey Hospitals report. ... Jersey,s hospital industry was on shaky financial ground long before the recent ...
Cached Medicine News:Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 4Health News:Experts Address State of HIV/AIDS Care in the Region Following Landmark Assessment Showing Widening Gaps in Social Services 2Health News:Experts Address State of HIV/AIDS Care in the Region Following Landmark Assessment Showing Widening Gaps in Social Services 3Health News:Experts Address State of HIV/AIDS Care in the Region Following Landmark Assessment Showing Widening Gaps in Social Services 4Health News:The physics of explosives and blast helmets 2Health News:The physics of explosives and blast helmets 3Health News:ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications 2Health News:ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications 3Health News:NJHA: Hospital Finances Show Troubling Trends 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: